Stronger European partnership key to unlocking investment and securing access to affordable medicines

Medicines for Ireland and Medicines for Europe convene Dublin policy forum to examine supply resilience, manufacturing investment and competitiveness

European policymakers must bring health and enterprise policy closer together to strengthen medicines supply, attract manufacturing investment and protect patients’ access to affordable treatments. That is the message from Medicines for Ireland and Medicines for Europe, which are jointly hosting a medicines policy forum in Dublin today (18.11.26). The forum is an official associated event of Ireland’s Presidency of the Council of the European Union.

Entitled “Securing Europe’s Medicines Future: Strengthening Resilience, Competitiveness and Supply Security”, the forum will examine practical steps to connect affordable patient access with sustainable supply. It brings together senior representatives from the pharmaceutical industry, European institutions and regulatory authorities, alongside policymakers and healthcare professionals.

Representing the off-patent medicines sector in Ireland and Europe respectively, Medicines for Ireland and Medicine for Europe see significant opportunities in generic, biosimilar and value-added medicines. They argue that these treatments are expanding patient access, improving care delivery and can support investment in Europe’s manufacturing base.

Realising that potential requires pricing, procurement and reimbursement policies that sustain affordability, reliable supply and a diverse supplier base. Both organisations are calling for predictable regulation and investment conditions that encourage companies to develop, manufacture and continue supplying medicines in Europe.

They warn that pricing pressures, rising production costs and growing regulatory requirements can collectively undermine the commercial viability of medicines supply. At the same time, geopolitical uncertainty and vulnerabilities in global supply chains reinforce the need for a coordinated European response.

Medicine for Ireland and Medicines for Europe are urging closer understanding between countries and across health, enterprise and finance authorities. Ensuring preparedness and better sharing of supply information should help anticipate shortages and strengthen Europe’s collective response to emerging risks. For both organisations, the priority is ensuring European pharmaceutical policy reforms deliver stronger competitiveness, resilient supply and lasting improvements in patient access.

Minister for Health Jennifer Carroll MacNeill TD will deliver the keynote address at the forum. Commenting, the Minister said: “Patients across Ireland and Europe must have confidence that they can access safe, effective and affordable medicines when they need them. Ireland’s Presidency of the Council of the European Union has played an important role in advancing policies that strengthen medicines security, support competitiveness and improve patient access.

“The Council’s adoption of the pharmaceutical package in September marked an important milestone, including provisions supporting timely generic competition and stronger security of supply. Alongside the Critical Medicines Act, this provides an important opportunity to strengthen Europe’s medicines resilience and improve affordable patient access.

“At national level, the Framework Agreement reached with Medicines for Ireland earlier this year demonstrates the importance of partnership between the State and industry. It supports greater predictability and security of supply for generic and biosimilar medicines, while recognising the contribution of value-added medicines.

“Across European and national policy, our shared task is to turn these commitments into practical improvements for patients. Continued collaboration will be essential to maintaining affordable access and preparing our health services for future needs.”

Donagh O’Leary, Chairperson of Medicines for Ireland, said: “Generic, biosimilar and value-added medicines underpin everyday patient care. Protecting access means ensuring Ireland remains a viable market where suppliers can invest, launch medicines and maintain reliable supply. Affordability and security of supply must go hand in hand. Pricing, procurement and reimbursement policies need to support competition and recognise the value of keeping medicines consistently available to patients.

“Our Framework Agreement with the State provides an important foundation to allow this to mature. The priority now is to translate its commitments into practical improvements, while ensuring wider European policies support sustainable supply. A stronger partnership between health and enterprise can help Ireland attract investment and realise the opportunities offered by biosimilars and value-added medicines.”

Adrian van den Hoven, Director General of Medicines for Europe, said: “Europe must recognise off-patent medicines manufacturing as a strategic capability. Decisions on procurement, energy, trade and regulation all influence manufacturers’ ability to sustain production and invest in the next generation of treatments.

“This requires a coordinated approach across health and industrial policy that recognises the combined pressures facing manufacturers. Efforts to strengthen resilience must also consider their impact on the long-term viability of supplying essential medicines.

“European solidarity must remain central to preparedness. Greater information sharing and coordinated responses can help Member States manage shortages without placing additional pressures on neighbouring countries. Strong international partnerships, alongside a robust European manufacturing base, will be essential to building a more secure and resilient medicines supply for the future.”